GREG BROWN - Partner
ImpediMed Limited
Baxter Diagnostics based from Australia (1983 to 90), UK (1990 to 1992) – 11 years, final role was Sales and Marketing Director for the UK
Roche – based from Switzerland (1992 to 1994), New York (1994 to 1997) – Senior Global Marketing Director for Molecular Diagnostics (PCR Virology). Launched HIV viral load with Pharma Inverase launch. HIV Viral load went form $6 million USD in 1995 to $160 million USD in 1997 – within 18 months
Digene Corporation Washington DC (1997 to 1999) ,Germany (1999 to 2004), Australia (2004 to 2006) – Officer and Vice President of Digene Corporation – NASDAQ listed Women’s health company with a $65 million market cap in 1998, in 2007 it sold for $1.6 Billion USD. Built revenues from $6 million to over $200 million during this period.
ImpediMed Limited - based from Australia (2004 to 2009) - CEO and Managing Director of ImpediMed – Publically listed on the ASX in October 2007, presently trading at a premium to its listing price in spite of market conditions. Company looking to commercialise a unique Australian medical device in the US, Europe and Japan. Primary focus is the US market.
Held Board positions with US companies – Nasdaq list Trinity Biotech, Impedance Cardiology Systems, CDIC for Diagnostics
